Case studies illustrating the management of trigeminal neuropathic pain using topical 5% lidocaine plasters

British Journal of Pain
7(2) 107–113
© The British Pain Society 2013
Reprints and permissions:
sagepub.co.uk/
journalsPermissions.nav
DOI: 10.1177/2049463713483459
bjp.sagepub.com

Nadine Khawaja, Zehra Yilmaz and Tara Renton

Abstract

Chronic trigeminal pain, with its severe related functional problems, is difficult to treat. Treatment is often empirically based on medications used for other chronic pain conditions. Systemic sodium channel and calcium channel blocking agents may cause a multitude of complications that are often poorly tolerated by the patient.

Aim: The aim of this case report was to assess the efficacy of topical 5% lidocaine plasters in reducing pain and reducing adjuvant medication in patients with orofacial neuropathic pain.

Method: Fourteen patients with chronic orofacial pain conditions referred to the oral surgery department were instructed to wear 5% lidocaine plasters for 12 hours each day over the painful area. The conditions included post-surgical neuropathy ($n = 10$), multiple sclerosis-related pain ($n = 1$), persistent idiopathic facial pain ($n = 1$), Ramsay Hunt syndrome (post-herpetic neuralgia, $n = 1$) and trigeminal neuralgia ($n = 1$). Data were collected on patient demographics, pain levels and medication.

Results: Pain levels improved in 12 out of 14 patients. Nine patients had a reduction in adjuvant medication, two of whom completely stopped adjuvant treatment.

Conclusion: This case series demonstrates that the use of 5% lidocaine plasters may play a useful role in the management of chronic trigeminal pain. A suggested novel approach for the management of orofacial pain, for clinicians, is presented.

Summary points

1. Management of chronic orofacial pain continues to be a major challenge to the clinician.
2. Patients are often placed on a multitude of medications in an attempt to alleviate pain without success.
3. Topical 5% lidocaine plasters, currently used for the management of post-herpetic neuralgia, offer the option of locally targeting trigeminal pain without the multiple side-effects of systemic medication.
4. This case series demonstrates that lidocaine plasters decrease verbal pain scores in extraoral, trigeminal and neuropathic pain, and reduce the use of other neuromodulatory agents in some, but not all, patients.
5. The plasters should be considered as a useful adjuvant in the management of pain in these patients.

Keywords

Chronic, lidocaine, neuropathic, pain, topical, trigeminal

Introduction

Chronic orofacial pain is comparable with other pain conditions in the body, accounting for between 20% and 25% of chronic pain conditions.¹ A recent cluster analysis classifying orofacial pain identifies neuralgia as

Department of Oral Surgery, King's College London, London, UK

Corresponding author:

Nadine Khawaja, Department of Oral Surgery, King's College London, King's College Dental Institute, Bessemer Road, London, SE5 9RS, UK.
Email: nadine.khawaja@kcl.ac.uk

Table 1. Classification of chronic orofacial pain based on cluster analysis².

Group 1: Neurovascular	Group 2: Neuralgia	Group 3: Idiopathic
<ul style="list-style-type: none"> • Migraine • Cluster headache • Tension-type headache • Cluster-tic syndrome • Medication overuse headache • Chronic daily headache • Temporal arteritis and hemicrania continua • SUNCT 	<ul style="list-style-type: none"> • Trigeminal neuralgia (typical/atypical) • Post-traumatic neuralgia • Post-herpetic neuralgia • Glossopharyngeal neuralgia • Neuropathic pain associated with generalised neuropathic conditions (diabetes, HIV, chemotherapy, multiple sclerosis) 	<ul style="list-style-type: none"> • Burning mouth syndrome • TMD pain • Persistent idiopathic facial pain

HIV: human immunodeficiency virus; SUNCT: short-lasting unilateral neuralgiform headache with conjunctival injection and tearing; TMD: temporomandibular joint disorder.

Table 2. Definitions of neuropathic pain types (International Association for the Study of Pain, 2007).

Neuropathic pain type	Definition	Diagnosis
Anaesthesia	Loss of sensation	On questioning patient, sensory testing
Paraesthesia	An abnormal sensation, whether spontaneous or evoked, which is not unpleasant	On questioning patient
Dysaesthesia	An unpleasant abnormal sensation (e.g. tingling/burning), may be spontaneous or evoked	On questioning patient
Hyperalgesia	An increased response to a stimulus which is normally painful	Increased response to sharp probe during sharp/blunt discrimination test or on questioning patient
Allodynia	Pain due to a stimulus which does not normally provoke pain	On questioning patient Mechanical allodynia: touch, kissing, bed sheets Hot allodynia: hot drinks/food Cold allodynia: cold drinks/food, cold wind

an individual pain group incorporating not only the more commonly acknowledged conditions such as trigeminal and post-herpetic neuralgia, but also post-traumatic neuralgia (Table 1).² Sensory nerve injury in post-traumatic neuralgia often results not only in numbness, which is a common misapprehension, but also in altered sensation and or pain (Table 2).

The impact of trigeminal pain is often underestimated, commonly interfering with speech, eating, kissing, make-up application, shaving and drinking; in fact, just about every social interaction we take for granted.³

Currently there is limited evidence-based management for chronic orofacial pain conditions. Carbamazepine is suggested for first-line medical management of trigeminal neuralgia (oxycarbamazepine for intolerant individuals)⁴ and conservative, reversible treatment is recommended initially for the treatment of temporomandibular joint disorder.⁵ Surgical interventions are effective in only some patients, and hence treatment is often empirically based on medications used for other chronic pain conditions, such as antidepressants or antiepileptics.⁴⁻⁶ Other conditions, including persistent idiopathic facial pain and post-surgical neuropathy, do not have recommended evidence-based care, but symptoms are also similarly medically managed.⁷ Such systemic medications may cause a multitude of complications

and are often poorly tolerated by patients.⁸ A topical approach to treating patients with chronic neuropathic orofacial pain may be more useful for such cases, especially in the avoidance of side-effects.

Lidocaine is a well-known local anaesthetic, sodium channel-blocking agent, regularly administered intraorally by dental clinicians. The 5% lidocaine plaster (Versatis®, Grünenthal UK Ltd, Stokenchurch, UK) is made of an adhesive material containing 700 mg lidocaine, which is applied to a polyethylene terephthalate backing.⁹ Currently these plasters are licensed, in the UK, solely for the management of localised post-herpetic neuralgia. The plasters are designed to be placed over the affected painful area, on intact skin, for a continuous 12-hour period each day and then must be removed for at least 12 hours. Continued pain relief during the day can be obtained through night-time application. The plaster itself may also have some limited protective properties against mechanical stimulation of the skin (e.g. cold wind or bed sheets) in patients suffering from allodynia. The plasters (10 × 14 cm) can be cut into smaller sizes to fit the chin and lip and extra-adhesive tape or plaster (Figure 1) can be placed over the patch for reinforcement.⁹

As with other local anaesthetics, the lidocaine patch results in sodium channel blockade inhibiting nerve conduction and stabilising neuronal membranes. This results in dampening of both peripheral nociceptor sensitisation and, ultimately, central nervous system hyperexcitability. Importantly, the lidocaine can penetrate the skin enough to result in an analgesic effect, but the amount is insufficient to produce a complete sensory block (i.e. numbness).¹⁰

Plasma levels of lidocaine remain insignificant (45 ng/mL after application of three plasters simultaneously in patients with post-herpetic neuralgia,¹¹ even with chronic use, thus eliminating systemic side-effects¹² and toxicity. The most common reported adverse reaction is skin irritation resulting in blisters, erythema and oedema, which tends to resolve spontaneously within a few minutes to a few hours.¹² Studies have suggested that the lidocaine patch may be effective for chronic neuropathic pain conditions other than post-herpetic neuralgia, including painful diabetic neuropathy and low back pain.¹⁰ Recently, its use in managing neuropathic pain associated with inferior alveolar nerve injury has been reported.¹³ The study reported success in one-quarter of patients when using the plasters alone but one-quarter stopped treatment with the plasters after they developed a rash.

In 2002, Katz et al. presented results from a prospective trial, at the American Pain Society's 20th Annual Scientific Meeting, demonstrating that the 5% lidocaine patch improved pain scores in treated patients with trigeminal post-herpetic neuralgia.¹⁴ To date, there are no other published trials on the effectiveness of lidocaine plasters in managing atraumatic chronic orofacial neuropathic pain. In this report, we present a case series aiming to assess whether the use of topical 5% lidocaine plasters reduces the level of pain and the use of adjuvant medication in patients with orofacial neuropathic pain.

Methods

Over a twelve month period (2008–2009) patients referred to the oral surgery department with extra-oral neuropathic trigeminal pain (Table 3) were treated with 5% lidocaine plasters (Versatis®).

At initial consultation, a thorough pain, medical and drug history was taken and a thorough physical examination performed. The same clinician assessed all the patients in this cohort. Standardised neurosensory tests were carried out including light touch, sharp-blunt discrimination, two-point discrimination and subjective function.¹⁵ Mechanical and cold stimuli were evoked by gently touching the neuropathic area with a dental probe and a piece of cotton wool sprayed with ethyl chloride, respectively. Patients were asked to

verbally report their pain on a scale ranging from 0 to 10 (where 0 represents no pain and 10 represents the worst pain imaginable) and explain how the condition affects them functionally on a day-to-day basis. Patients were instructed to wear one plaster over the affected site (Figure 1) for a continuous 12-hour period each day, preferably at night. There was no alteration to the patients' other medication and they were advised that the plasters would not interfere with their normal medication regimen.

Patients were reviewed following continuous use of the medicated plasters for a minimum of 4 weeks. Another verbal pain report assessment was attained along with an explanation of any change in daily function and symptoms. The patients' medication use was again recorded at review to ascertain if a change in adjuvant medication had occurred as a result of treatment with topical lidocaine plasters. Patients' general comments were also sought at review to clarify if any problems arose using these plasters.

Pain scores prior to and after the use of the plasters were compared using the Student's *t*-test for analysis of the means, at a 95% confidence interval ($p < 0.05$).

Results

Fourteen patients were referred to the oral surgery department in a 12-month period (Table 3). The pain conditions involved the mandibular division of the trigeminal nerve (V3); post-surgical neuropathy affecting the inferior alveolar nerve (IAN) dermatome ($n = 10$), Ramsay Hunt syndrome (post-herpetic neuralgia; $n = 1$), trigeminal neuralgia ($n = 1$), multiple sclerosis ($n = 1$) and the maxillary division of the trigeminal nerve (V2) in the form of persistent idiopathic facial pain ($n = 1$).

The largest group in this cohort was those with post-surgical neuropathic pain in relation to dental procedures. Thirty per cent of the dental procedures causing IAN injury were wisdom tooth removal or implant therapy. Endodontic therapy, extracted lower premolars and surgical removal of a mucocoele accounted for the remaining surgical causes. All pain conditions in this cohort affected extraoral sites of the maxillary and mandibular divisions of the trigeminal system only.

The mean age was 59 years old (range 27–82 years) with a male to female ratio of 1:6. Duration of symptoms on initial presentation to the oral surgery department ranged from 1 to 9 months.

The majority of patients suffered from more than one type of alerted sensation. Most of them demonstrated hyperalgesia on sensory testing (Figure 2). All patients reported associated functional problems, with half of patients reporting difficulties with sleeping and

Table 3. Data of collected cases.¹⁶

Age	Sex	Aetiology	Neuropathic area	Neuropathic symptoms	Verbal pain scores (0–10)			Medication reduced/stopped?	Recommend?
					Pre-versatis	Post-versatis	Difference		
27	F	Third molar surgery LR8	RIAN	HYP A, MA, D,	8	8	0	N	N
64	F	Implant	LIAN	HYP A	10	10	0	N	N
54	F	Root canal LL7	LIAN	HYP A	7	4	3	Y	Y
56	F	Ramsay Hunt syndrome	RION	HYP A	8	2	6	Y	Y
67	F	Implant	R+LIAN	HYP A, MA, CA, HA	9	4	5	Y	-
74	M	LA extraction LL5	LIAN	HYP A, MA	9	2	7	Y	Y
61	F	Atypical facial pain	LION	HYP A, MA, D	10	5	5	Y stop	Y
82	M	Trigeminal neuralgia	RION	MA	8	7	1	N	Y
66	F	LA extraction LR8	RIAN	HYP A, MA	7	5	2	N	Y
80	F	Implant	R+LIAN	D	9	7	2	Y	Y
75	F	LA extraction LL5	LIAN	HYP A, MA, D	7	4	3	N	Y
29	F	Third molar surgery LL8	LIAN	CA	9	1	8	Y	Y
41	F	Excision myxoid lesion right mandible	RIAN	CA HYP A	7	3.5	3.5	Y stop	-
37	F	Multiple sclerosis V3 neuralgia	RIAN	MA	9	6	4	Y	-

CA: cold allodynia; D: dysaesthesia; F: female; HA: hot allodynia; HYP A: hyperalgesia; LA: local anaesthetic; LIAN: left inferior alveolar nerve dermatome; LION: left infraorbital nerve dermatome; M: male; MA: mechanical allodynia; RIAN: right inferior alveolar nerve dermatome; RION: right infraorbital nerve dermatome.

Figure 1. Photograph demonstrating how to wear the plaster on the face (a) and covered with foundation make-up (b).

Figure 2. The proportion of reported symptoms at initial presentation.

Figure 3. The proportion of reported functional problems at initial presentation.

eating (Figure 3). Other functional problems included drinking, kissing, make-up application, going outside and shaving. The functional problems were entirely attributable to elicited or ongoing pain in or around the orofacial region. The types of pain reported by the patients were spontaneous, evoked or constant pain, demonstrating features of hyperaesthesia, dysaesthesia and paraesthesia.

Twelve out of fourteen patients responded to topical lidocaine plasters. There was a reduction in the level of ongoing pain from 9.8 (range 7–10) to 4.7 (3.5–10) after using the topical 5% lidocaine plasters ($p < 0.05$; 95% CI) (Figure 4). Eleven patients showed a reduction in pain (≥ 2 points) on the verbal rating scale following use of the plasters.¹⁷ Nine out of the twelve patients who responded to lidocaine plasters also reported a reduction in the use of adjuvant therapies, including anticonvulsants and tricyclic antidepressants, two of whom completely stopped adjuvant therapy. Nine out of fourteen patients would recommend the plasters to other sufferers.

Topical lidocaine treatment was unsuccessful in two patients: one patient did not feel any pain relief and the other reported a localised rash in the area covered by the plaster. The rash spontaneously resolved following removal of the plaster. This was the only reported side-effect.

Discussion

This is the first case series to demonstrate that topical 5% lidocaine plasters may be used as an adjunct in the management of patients with chronic trigeminal neuropathic pain of both traumatic and atraumatic nature. Multiple studies have demonstrated the efficacy of 5%

lidocaine plasters in the management of post-herpetic neuralgia, and hence has been recommended as its first-line therapy.¹⁸ However, there are relatively few reports using topical lidocaine plasters for other chronic pain conditions, including trigeminal pain.¹⁰

A recent study demonstrated a significant reduction in three chronic pain conditions following use of the 5% lidocaine patch: post-herpetic neuralgia, painful diabetic neuropathy and low back pain.¹⁷ In addition, a reduction in brain activity following a 2-week treatment of lidocaine plasters in chronic low back pain (medial prefrontal cortex) and knee osteoarthritis (thalamus) patients has been reported using serial functional magnetic resonance imaging.¹⁹ This suggests that chronic pain conditions that demonstrate common neuropathic symptomatology with post-herpetic neuralgia may be successfully managed using the lidocaine plaster.

Neuropathic pain often responds poorly to conventional analgesics (e.g. non-steroidal anti-inflammatory drugs, paracetamol, opioid analgesics). Their effect is potentiated when they are used in combination with antidepressants and anticonvulsant medications. Other topical preparations often rely on absorbance of the analgesic to exert a systemic effect (e.g. fentanyl plasters), and hence not reducing potential associated side-effects. National Institute for Health and Clinical Excellence guidelines, issued in March 2009, recommend amitriptyline [number needed to treat (NNT) = 3.6] or pregabalin (NNT = 4–11, depending on dose) as first-line therapy treatment options for adults with neuropathic pain,¹⁶ giving prescription guidance to practitioners. Topical capsaicin cream has been reported to be effective in some neuropathic pain conditions, but comes with the unpleasant side-effect of an initial stinging sensation.²⁰

Figure 4. Visual analogue scale (VAS) pain scores before and after patches.

This patient cohort presented with moderate to severe pain affecting extraoral sites of maxillary or mandibular divisions of the trigeminal nerve. This often has high functional implications given the affected site. The functional disability associated with trigeminal pain is rarely reported²¹ and requires better scrutiny. Alarming, the majority of this patient cohort had severe neuropathic pain associated with post-surgical neuropathy. Predominantly, the surgical cause of neuropathic pain was either removal of wisdom teeth or implant placement. The iatrogenesis of post-traumatic neuralgia also compounds the negative psychological effects for these injuries,²² heavily impacting the patient's ability to cope with chronic pain.

Pain levels were reduced using 5% lidocaine plasters for trigeminal pain as previously reported in other pain conditions, highlighting that this treatment method may be a useful adjunctive tool for the management of chronic orofacial pain. The reduction in pain levels may be related to the moderate/severe level of pain reported by these patients. It remains unknown if this treatment would be as effective in a patient group with low/moderate pain levels.

Most patients were happy wearing the plasters, however, many patients commented on the difficulty of maintaining adhesion of the plasters with micropore tape. There was a single adverse event of rash formation. Most patients reported that these minor issues were outweighed by the benefits of use. Interestingly, several patients commented that the plasters significantly assisted with breakthrough pain, particularly to cold allodynia caused by exposure of the face to cold air resulting in excruciating pain. As these plasters are

adhesive, they are not applicable to intraoral sites and are limited to extraoral use only.

The successful use of lidocaine plasters in controlling chronic neuropathic pain in clinical practice was demonstrated by a multicentre study that reported a 30% reduction in overall pain intensity within the first 2–3 weeks with continuous further reductions until end of observation at 12 weeks.²³ The duration of use of the topical lidocaine plasters in this study ranged from 4 to 19 weeks. Further attenuation of the patient to this modality of treatment may be possible and worthy of determination. Further use in more localised pain conditions such as persistent dentoalveolar pain (PDAP, atypical odontalgia) may also be possible.

Treatment with lidocaine plasters have been demonstrated not only to reduce the pain experience but also to improve anxiety and depression scores and overall quality of life scores.²³

It is worth remembering that neuropathic pain is not entirely dependent on peripheral afferent input but may also be as a result of central sensitisation and plasticity. This indicates that the sole use of lidocaine plasters may be insufficient to render patients completely pain free. If, however, they are used in combination with adjunctive systemic medication (e.g. pregabalin) they can help control pain and limit side-effects by lowering the effective dose of the systemic medication. Reduction of adjuvant pain medication was observed in nine patients, two of whom managed to stop their multidrug regimen entirely.

It may be suggested that early use of lidocaine plasters can help limit peripheral nerve excitation, preventing central sensitisation and improving successful pain management.

The limitations associated with this case report are acknowledged, including the small sample size and heterogeneous nature of the sample (surgical and non-surgical neuropathy). Further work will assess whether patients experience continued modulation of neuropathy after long-term use.

Conclusion

Management of chronic orofacial pain remains a significant challenge. Owing to the common and unacceptable levels of side-effects from antidepressant or anticonvulsant drugs, many patients find adhering to therapy extremely difficult, further compromising their pain management. Five per cent lidocaine plasters have been shown to be a useful adjunct in the treatment of orofacial pain and most patients found them acceptable. These recommendations are preliminary in nature and further studies are needed to assess the efficacy of topical 5% lidocaine plasters in a larger cohort of patients (randomised, double-blind, placebo-controlled trials).

Acknowledgements

Thank you to our patients for undertaking this novel treatment with such positivity.

Conflict of interest

The author declares that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Madland G and Feinmann C. Chronic facial pain: a multidisciplinary problem. *J Neurol Neurosurg Psychiatry* 2001; 71(6): 716–719.
2. Woda A, Tubert-Jeannin S, Bouhassira D, Attal N, Fleiter B, Goulet JP, et al. Towards a new taxonomy of idiopathic orofacial pain. *Pain* 2005; 116(3): 396–406.
3. Ziccardi VB and Assael LA. Mechanisms of trigeminal nerve injuries. *Atlas Oral Maxillofac Surg Clin North Am* 2001; 9(2): 1–11.
4. Jorns TP and Zakrzewska JM. Evidence-based approach to the medical management of trigeminal neuralgia. *Br J Neurosurg* 2007; 21(3): 253–261.
5. Cooper BC. Temporomandibular disorders: a position paper of the International College of Cranio-Mandibular Orthopedics (ICCMO). *Cranio* 2011; 29(3): 237–244.
6. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C and Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2004; 63(6): 959–965.
7. Zakrzewska JM. Facial pain: an update. *Curr Opin Support Palliat Care* 2009; 3(2): 125–130.
8. O'Connor AB and Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. *Am J Med* 2009; 122(10 Suppl): S22–32.
9. Grünenthal UK Ltd. Versatis (lidocaine patch 5%). Patient product information leaflet. January 2012, Uxbridge, UK: Grünenthal UK Ltd.
10. Mick G and Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster – a review. *Curr Med Res Opin* 2012; 28(6): 937–951.
11. Medicines and Healthcare products Regulatory Agency. Public assessment report; lidocaine 5% medicated plaster, 2009. London, UK: Medicines and Healthcare products Regulatory Agency.
12. Gammaitoni AR, Alvarez NA and Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. *Am J Health Syst Pharm* 2002; 59(22): 2215–2220.
13. Renton T and Yilmaz Z. Managing iatrogenic trigeminal nerve injury: a case series and review of the literature. *Int J Oral Maxillofac Surg* 2012; 41(5): 629–637.
14. Katz NP, Davis MW, Dworkin RH. Topical lidocaine patch produces a significant improvement in mean pain scores and pain relief in treated PHN patients: results of a multicenter open-label trial. *American Pain Society 20th Annual Scientific Meeting*, April 19–22, 2001. Phoenix, AZ. Glenview, IL, USA: American Pain Society.
15. Khawaja N and Renton T. Case studies on implant removal influencing the resolution of inferior alveolar nerve injury. *Br Dent J* 2009; 206(7): 365–370.
16. National Institute for Health and Clinical Excellence. The pharmacological management of neuropathic pain in adults in non-specialist settings. Available at: <http://www.nice.org.uk/cg96> (2010, March 2010).
17. Farrar JT, Young JP Jr., LaMoreaux L, Werth JL and Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* 2001; 94(2): 149–158.
18. Davies PS and Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. *Drugs* 2004; 64(9): 937–947.
19. Baliki MN, Geha PY, Jabakhanji R, Harden N, Schnitzer TJ and Apkarian AV. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. *Mol Pain* 2008; 4: 47.
20. Wolff RF, Bala MM, Westwood M, Kessels AG and Kleijnen J. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. *Acta Neurol Scand* 2011; 123(5): 295–309.
21. Renton T. An update on pain. *Br Dent J* 2008; 204(6): 335–338.
22. Abarca M, van Steenberghe D, Malevez C, De Ridder J and Jacobs R. Neurosensory disturbances after immediate loading of implants in the anterior mandible: an initial questionnaire approach followed by a psychophysical assessment. *Clin Oral Investig* 2006; 10(4): 269–277.
23. Uberall MA and Muller-Schwefe GH. Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice. *Curr Med Res Opin* 2012; 28(6): 901–909.